EUVIMEDEUVIMED entdecken
Crossref

Donor‐Derived Cell‐Free DNA Levels and Prediction of Resolution of Rejection in Kidney Transplant Recipients

Elaine Ku iD, Erica Winnicki, Sabrina Legaspi, Feng Lin, Charles E McCulloch, Deborah Adey

Clinical Transplantation · 2026

DOI: 10.1111/ctr.70443 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Transplantation, 2026. Verfasst von Elaine Ku und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Graft Rejection, Cell-Free Nucleic Acids, Kidney Failure, Chronic. Die Arbeit nennt 18 Literaturangaben. Gefördert von: Natera.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The gold standard approach to the diagnosis of rejection in kidney transplant recipients currently relies on tissue obtained during biopsies. However, repeat performance of biopsies is cumbersome, and use of dd‐cfDNA in conjunction with eGFR may help inform whether ongoing rejection may be persistent after a diagnosis of rejection is made by biopsy and anti‐rejection treatment administered. In this single‐center prospective study, 52 patients with rejection were followed longitudinally over time with quarterly dd‐cfDNA measurements, of whom 78% had repeat biopsies to confirm the presence or absence of persistent rejection. With every 1 percentage point higher baseline (“first”) dd‐cfDNA levels drawn at time of enrollment, the odds of persistent rejection were 1.35 (95% CI 1.18‐1.55) higher. With every 1 percentage point increase in the slope of dd‐cfDNA levels over time, the odds of persistent rejection were 1.62 times higher (95% CI 1.10‐2.38). Models including only baseline and the slope of dd‐cfDNA provided moderate risk discrimination for rejection (c = 0.73), which improved to c = 0.75 with the addition of eGFR at baseline and change in eGFR over time. Monitoring of dd‐cfDNA may offer reasonable discrimination of the likelihood of persistent rejection following anti‐rejection therapy. Further validation of these findings is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationGraft RejectionCell-Free Nucleic AcidsKidney Failure, ChronicTissue DonorsBiomarkersHumansFemaleProspective StudiesFollow-Up StudiesPrognosisMaleGlomerular Filtration RateMiddle AgedKidney Function TestsGraft SurvivalAdultRisk FactorsTransplant Recipients

Stichwörter der Autor:innen

Cell free DNAkidney transplantrejection

Substanzen

Cell-Free Nucleic AcidsBiomarkers

Autor:innen und Institutionen

  • Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • Department of Pediatrics, University of California San Francisco, San Francisco, California, USA.
  • Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.

ORCID-Profile: Elaine Ku

Förderung

  • Natera

Zitieren

APA

Ku, E., Winnicki, E., Legaspi, S., Lin, F., McCulloch, C. E., & Adey, D. (2026). Donor‐Derived Cell‐Free DNA Levels and Prediction of Resolution of Rejection in Kidney Transplant Recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.70443

Vancouver

Ku E, Winnicki E, Legaspi S, Lin F, McCulloch CE, Adey D. Donor‐Derived Cell‐Free DNA Levels and Prediction of Resolution of Rejection in Kidney Transplant Recipients. Clinical Transplantation. 2026. doi:10.1111/ctr.70443

BibTeX
@article{Ku2026,
  author = {Ku, Elaine and Winnicki, Erica and Legaspi, Sabrina and Lin, Feng and McCulloch, Charles E and Adey, Deborah},
  title = {Donor‐Derived Cell‐Free DNA Levels and Prediction of Resolution of Rejection in Kidney Transplant Recipients},
  journal = {Clinical Transplantation},
  year = {2026},
  doi = {10.1111/ctr.70443}
}
Kostenlos starten →